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The variation in sequence and length in the C-terminal region among members of the unique PE (Pro-Glu)
and PPE (Pro-Pro-Glu) protein families of Mycobacterium tuberculosis is a likely source of antigenic variation,
giving rise to the speculation that these protein families could be immunologically important. Based on in silico
analysis, we selected a hypothetical open reading frame (ORF) encoding a protein belonging to the PPE family
and having epitopes with predictably higher antigenic indexes. Reverse transcriptase PCR using total RNA
extracted from in vitro-cultured M. tuberculosis H37Rv generated an mRNA product corresponding to this gene,
indicating the expression of this ORF (Rv2430c) at the mRNA level. Recombinant protein expressed in
Escherichia coli was used to screen the sera of M. tuberculosis-infected patients, as well as those of clinically
healthy controls (n  10), by enzyme-linked immunosorbent assay. The panel of patient sera comprised sera
from fresh infection cases (category 1; n  32), patients with relapsed tuberculosis (category 2; n  30), and
extrapulmonary cases (category 3; n  30). Category 2 and 3 sera had strong antibody responses to the PPE
antigen, equal to or higher than those to other well-known antigens, such as Hsp10 or purified protein
derivative (PPD). However, a higher percentage of patients belonging to category 1, as opposed to clinically
healthy controls, showed stronger antibody response against the PPE protein when probed with anti-immu-
noglobulin M (IgM) (71 versus 37.5%) or anti-IgG (62.5 versus 28.12%). Our results reveal that this PPE ORF
induces a strong B-cell response compared to that generated by M. tuberculosis Hsp10 or PPD, pointing to the
immunodominant nature of the protein.
About 10% of the genome of Mycobacterium tuberculosis
codes for the PE and PPE families of proteins (7), which are
glycine rich and are exclusive to M. tuberculosis. The 69 mem-
bers of the PPE protein family have a conserved N-terminal
domain that comprises 180 amino acids followed by C-ter-
minal segments that vary markedly in sequence and length.
These proteins fall into three groups, one of which constitutes
the MPTR class characterized by the presence of multiple
tandem copies of the motif Asn-X-Gly-X-Gly-Asn-X-Gly. The
second subgroup contains a characteristic well-conserved mo-
tif, Gly-X-X-Ser-Val-Pro-X-X-Trp, around position 350. The
proteins in the third group are unrelated except for the pres-
ence of the common PPE domain. The subcellular locations of
a few PPE proteins are known (6, 25), and in only one case (7),
that of a lipase (Rv3097), has a function been suggested. There
are few studies supporting the notion that PE and PPE pro-
teins could be of functional importance (7, 23). It is widely
speculated that they could be responsible for generating anti-
genic variation (1, 4, 6, 8, 12, 27). However, the effects the PPE
family proteins, unique in their protein sequences and possible
structure, may have on the immune system have not been well
documented. Furthermore, a qualitative and quantitative im-
mune response to PPE proteins in a clinical setting has not
been shown. Since 180 amino acid residues in the N-terminal
regions of PPE proteins are conserved, it is interesting to
speculate that the variation in sequence and length in the
C-terminal region could represent a source of antigenic vari-
ability.
Based on in silico analysis and DNA microarray expression
data (24), we selected an ORF, Rv2430c, whose product dis-
plays a high antigenic index and evaluated its importance in
eliciting immune responses in a panel of human sera obtained
from three well-classified categories of patients: (i) those re-
porting TB for the first time, (ii) those presenting with a re-
lapse of TB, and (iii) those with extrapulmonary cases. Clini-
cally healthy human sera were used as controls to compare the
immunological responses to the protein. Enzyme-linked immu-
nosorbent assay (ELISA) using the recombinant protein
showed good specificity and sensitivity, suggesting that the
product of this PPE family ORF, Rv2430c, induces a strong
B-cell response in infected subjects.
MATERIALS AND METHODS
In silico analysis of Rv2430c. In silico pattern search analysis of the PPE family
was carried out to classify the products of the various ORFs into three subgroups.
Products of ORFs with200 amino acids and belonging to the third subgroup of
the PPE family were further analyzed using protein analysis software (Protean
version 4.0, Lasergene Navigator; DNASTAR Inc., Madison, Wis.) to calculate
their antigenic indexes.
RNA extraction and reverse transcriptase (RT) PCR. RNA was extracted
from 109 H37Rv cells, cultured in vitro in Middlebrook 7H9 medium supple-
mented with albumin-dextrose complex according to the Qiaquick total RNA
extraction kit (Qiagen Inc.) instructions, dissolved in 50 l of nuclease-free
water, and stored at 70°C until further use. First-strand synthesis was carried
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out using avian myeloblastosis virus reverse transcriptase. This was followed by
heat denaturation to inactivate the enzyme. Subsequent second-strand synthesis
was performed using Tfl polymerase. The PCR product was visualized by elec-
trophoresis in a 1% agarose gel.
Expression and purification of the recombinant protein encoded by Rv2430c.
Genomic DNA of H37Rv was extracted using the Genome Extraction kit pro-
vided by Epicentre Technologies, as described earlier (26). The Rv2430c gene
was PCR amplified from the genomic DNA of H37Rv using upstream (5-GGA
TCCATGCATTTCGAAGCGTAC-3) and downstream (5-AAGCTTCTAAG
TGTCTGTACGCGATGA-3) primers. BamHI and HindIII sites were incorpo-
rated in the 5 and 3 ends of the primers, respectively. The purified fragment was
ligated into the pGEMT-Easy vector (Promega Inc.), and the recombinant clone
carrying the Rv2430c insert was confirmed by DNA sequencing (ABI Prism 377
DNA Sequencer; PE Biosystems). The insert was then subcloned as a BamHI
and HindIII fragment into the PQE30 expression vector (Qiagen Inc.) to gen-
erate the plasmid construct PQERv2430c carrying Rv2430c as an N-terminal
histidine-tagged fusion. PQERv2430c was transformed into the host M15pREP4
strain of Escherichia coli. A single colony of E. coli strain M15pREP4 harboring
PQERv2430c was inoculated into 5 ml of Luria-Bertani broth with the appro-
priate antibiotics (100 g of ampicillin/ml and 25 g of kanamycin/ml) and grown
overnight at 37°C with constant agitation; 100 l of this overnight culture was
inoculated into 5 ml of Luria-Bertani broth with the appropriate antibiotics and
grown to an optical density at 590 nm of 0.6, at which time expression was
induced with 1 mM IPTG. A separate aliquot of uninduced culture was kept as
a control. Cells were harvested 3 h postinduction, suspended in 1 SDS sample
buffer, and denatured by being heated at 100°C for 10 min. The recombinant
FIG. 1. In silico analysis of PPE ORFs. Only the ORFs belonging to subgroup 3 and encoding products 200 amino acids in length were
subjected to analysis. The presence of stretches of high antigenic index are shown. The x axis indicates the ORF product length in amino acids,
while the y axis represents the antigenic index.
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protein was purified to homogeneity with the QIA Expressionist kit (Qiagen
Inc.).
Serological characterization of the recombinant protein. ELISAs were per-
formed in 96-well microtiter plates (Corning Costar) coated with the recombi-
nant Rv2430c protein. After overnight incubation at 4°C, the plates were washed
three times with phosphate-buffered saline (PBS) buffer and blocked with 200 l
of blocking buffer (PBS containing 1% bovine serum albumin) for 1 h at 37°C.
The plates were then washed three times with PBS-Tween wash buffer (0.05%
Tween 20 in 1 PBS, pH 8.0) and incubated for 1 h at 37°C with human sera (1:
200 dilution in blocking buffer). The plates were washed with PBS-Tween and
further incubated with either anti-human immunoglobulin G (IgG)-horseradish
peroxidase (HRP) or anti-human IgM-HRP (Sigma). HRP activity was detected
using a chromogenic substance, o-phenylenediamine tetrahydrochloride (Sigma),
in citrate-phosphate buffer (pH 5.4) and 1 l of H2O2 (Qualigens, India)/ml. The
reactions were terminated using 1 N H2SO4, and the absorbance values were
measured at 492 nm in an ELISA reader (Bio-Rad).
Study population. Serum samples were obtained from 92 TB patients who had
reported to the Mahavir Hospital and Research Centre, Hyderabad, India, and
10 clinically healthy donors. The 92 patients belonged to three well-defined
categories. Category 1 (n  32) comprised patients who had contracted the
pathogen for the first time and had no history of TB treatment. Category 2 (n 
30) comprised patients with relapsed TB, i.e., who were treated earlier for TB but
the symptoms resurfaced after completion of the treatment. Category 3 (n  30)
comprised patients with extrapulmonary TB in which the disease was confirmed
by tissue biopsy. In the cases of category 1 and category 2 patients, diagnosis was
confirmed by examination of the sputum (acid-fast bacillus smear positive).
Clinically healthy donors were vaccinated with Mycobacterium bovis BCG. The
study was carried out after approval from the Institute Bioethics Committee.
Statistical analysis. Student’s t test was used for analysis of statistical signifi-
cance (P value). Graphpad Quickcalcs (online t test calculator [http://www
.graphpad.com/quickcalcs/ttest1.cfm]) was used for this purpose.
RESULTS
The product of the hypothetical PPE ORF Rv2430c has a
high antigenicity profile score and is expressed at the mRNA
level. In silico analyses of the PPE ORF products, 200 amino
acids in length, belonging to subgroup 3 of the PPE family (7)
were carried out. Rv2430c and Rv3425 displayed major anti-
genic stretches (Fig. 1) with peak values of 3.0. However, an
analysis of the microarray expression data (24) identified
Rv2430c as one of the overexpressed genes in an IdeR mutant
of M. tuberculosis, and it was thereby implicated in pathogen-
esis. Rv2430c was thus selected for our study. Rv2430c was
further subjected to detailed analysis to predict its likely struc-
ture through various algorithms. The Predict Protein server
(http://www.embl-heidelberg.de/predictprotein/) gave a very
low score for Rv2430c, pointing to the unlikely possibility that
this ORF encoded a transmembrane protein (data not shown).
To check whether the hypothetical Rv2430c indeed repre-
sented a functional gene, the mRNA extracted from in vitro-
cultured H37Rv cells was used as a template for reverse tran-
scription followed by PCR. The RT-PCR product was
fractionated on a 1% agarose gel. A 597-bp band was observed
upon staining with ethidium bromide, indicating that the ORF
was expressed at the mRNA level in the liquid cultures of M.
tuberculosis (Fig. 2A). The ORF Rv2430c was expressed as a
His-tagged fusion protein in E. coli (Fig. 2B) and used for
immunological studies.
The recombinant PPE protein Rv2430c displays strong B-
cell responses during infection with TB. Having shown that the
ORF encoding RV2430c of M. tuberculosis was expressed at
the mRNA level, experiments were designed to evaluate the
immune response of TB patients to recombinant Rv2430c PPE
protein. For this, the recombinant Rv2430c protein was used to
screen the TB patient sera by ELISA, using anti-human IgG-
HRP and anti-human IgM-HRP as conjugates. The humoral
immune responses directed against the recombinant protein by
patients with TB and healthy controls were compared. The
data (Fig. 3) reveal that the sera of all the infected patients
mounted significantly higher antibody responses against
Rv2430c than those of the healthy controls (P 0.0001). Since
negligible antibody responses were obtained in the healthy-
control group (Fig. 3), it is likely that this protein is expressed
during the course of M. tuberculosis infection, and it may be
associated with disease manifestation and progression.
Immunodominant nature of Rv2430c. Since all the patients
infected with TB revealed strong humoral responses against
Rv2430c compared to the healthy controls, it was of interest to
compare the antibody responses in various clinical categories
and also to evaluate whether Rv2430c is immunodominant.
For this, we chose recombinant Hsp10 of M. tuberculosis, which
is a well-known immunodominant antigen of M. tuberculosis
(28). Figure 4 clearly shows that strong antibody responses
were elicited against Rv2430c in all three study groups (cate-
gory 1, category 2, and category 3). Rv2430c elicited statisti-
FIG. 2. (A) Transcription of hypothetical PPE ORF Rv2430c. RNA extracted from the virulent H37Rv laboratory strain of M. tuberculosis was
used in an RT-PCR. A 597-bp RT-PCR product was observed after electrophoresis in a 1% agarose gel (lane 1). Lane M is the 100-bp DNA
molecular size marker run alongside. The arrow on the right indicates the position of the 597-bp PCR product. (B) Expression and purification
of the recombinant PPE protein. The recombinant protein was expressed in strain M15pREP4 of E. coli and was purified to homogeneity using
the NiNTA protein purification kit. Lane 1, marker; lane 2, purified protein. The arrow on the right indicates the position of the 23-kDa protein.
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cally significant immune responses compared to Hsp10 (P 
0.003) in patients with fresh infections (Fig. 4A). Patients be-
longing to categories 2 and 3 exhibited Rv2430c-specific anti-
body equivalent to that for Hsp10 (Fig. 4B and C). Since the
PPD antigen of M. tuberculosis is also used to diagnose TB
infection (2, 15, 29), we compared the immunopotentiality of
Rv2430c over PPD only in cases of fresh infection (Fig. 4A).
The results clearly indicated that the PPE protein Rv2430c is
far more immunogenic and could elicit a stronger B-cell re-
sponse than PPD. Sera from the fresh-infection category re-
sponded better against the Rv2430c antigen than against PPD
(P  0.0001) (Fig. 4A).
In order to compare the serological sensitivities of Rv2430c
and Hsp10, the data presented in Fig. 4 were recalculated as
percentages of individuals showing absorbances above 0.65 at
492 nm. Although only 28.12% of individuals with fresh infec-
tions mounted strong antibody responses of the IgG type to
Hsp10, a very high percentage of individuals (62.5%) recog-
nized Rv2430c (Fig. 5A). Similar conclusions could be drawn
when IgM antibodies were assayed (Rv2430c versus Hsp10, 71
versus 37.5%) (Fig. 5B). From these results, it is apparent that
Rv2430c shows better reactivity vis-a-vis Hsp10 to sera from
patients with fresh infection than to those of relapsed or ex-
trapulmonary-TB patients. Our results, therefore, convincingly
demonstrate the immunodominant nature of the product of
the hypothetical PPE ORF Rv2430c.
FIG. 3. The recombinant Rv2430c PPE protein elicits strong anti-
body responses in M. tuberculosis-infected patients as opposed to
healthy controls. ELISA reactivities of IgG anti-Rv2430c antibodies
were assayed in sera of either M. tuberculosis-infected patients or
healthy controls (P  0.0001). Symbols, patient population.
FIG. 4. PPE Rv2430c protein shows strong reactivities to sera from all three patient categories. Reactivities to both recombinant Rv2430c and
Hsp10 of M. tuberculosis in the three categories of patients were estimated by ELISA. The patients belonging to categories 2 (B) and 3
(C) displayed similar antibody responses to both antigens. However, the antibody responses of category 1 patients (A) to Rv2430c were higher than
those to Hsp10 (P  0.003) or PPD (P  0.0001).
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DISCUSSION
The 69 members of the PPE protein family have a conserved
N-terminal domain that comprises 180 amino acids followed
by C-terminal segments that vary markedly in sequence and
length (7). Based on our pattern search analysis of the
TubercuList database (http://genolist.pasteur.fr/Tubercu-
List/), these proteins were categorized into three groups.
Subgroup 1, represented by 20 members, constitutes the
MPTR class characterized by the presence of multiple tan-
dem copies of the motif Asn-X-Gly-X-Gly-Asn-X-Gly. The
second subgroup, comprising 21 members, contains a char-
acteristic well-conserved motif, Gly-X-X-Ser-Val-Pro-X-X-
Trp, around position 350. The proteins of the third sub-
group, with 28 members, are unrelated except for the
presence of the common PPE domain. That ORF products
across the subgroup do not react immunologically was evi-
dent from our studies with Rv2608 (unpublished data).
Rv2430c belongs to the third subgroup. ORFs belonging to
the third subgroup with coding capacities of 200 amino
acids were shortlisted. This shortlist was further narrowed
down based on two very important criteria, namely, the
antigenic profile and the association of the ORF with patho-
logical conditions as evident from DNA microarray expres-
sion data (24). Rv2430c and Rv3425 were the ORFs with the
highest antigenicity indexes. DNA microarray results dem-
onstrated that of these two ORFs, Rv2430c was one of the
genes induced in an IdeR mutant of M. tuberculosis (24),
pointing to its possible role in pathogenesis. Rv2430c was
accordingly shortlisted and evaluated for the role of its
product as an antigen in a clinical setting.
The ORF was shown to be RT-PCR positive, pointing to the
likelihood that it is expressed during infection. The Rv2430c
ORF was expressed in E. coli, and the recombinant protein was
purified and tested for its ability to recognize IgG antibody in
the sera of TB patients and healthy individuals.
The TB patients used in our study represent a heteroge-
neous population, including fresh infection cases characterized
by patients who contracted the pathogen for the first time
(category 1); relapsed cases, in which the disease resurfaced
after the completion of treatment (category 2); and extrapul-
monary cases, which are mostly sputum negative (category 3).
The immune response profiles of Rv2430c in different clinical
categories were studied. The PPE protein Rv2430c was found
to be recognized by antibodies in the sera of infected patients
in ELISA with a serum dilution of 1:200, whereas poorer
ELISA reactivity was observed for the sera of all of the healthy
individuals. The presence of antibodies to Rv2430c in sera
from TB patients (Fig. 3) and their absence in sera from
healthy individuals suggests that the protein is expressed in
vivo during active infection with M. tuberculosis and that the
native molecule is immunogenic.
Several reports have emphasized the observation of a lack of
sufficient immune responses in TB patients against many
promising serodiagnostic antigens of M. tuberculosis. This fact
is more distressing in cases of fresh infection, where in a ma-
jority of the cases the immune system is not sufficiently primed
to elicit a strong antibody response against most of the M.
tuberculosis antigens. The recombinant Rv2430c protein was
very strongly recognized by all three categories of patients,
including the fresh-infection group (category 1). The members
FIG. 5. Serological sensitivities of PPE Rv2430c and Hsp10 as a function of percentages of individuals. (A) The results shown in Fig. 4 were
recalculated as percentages of individuals showing A492 values of 	0.65. The anti-IgG responses against Rv2430c or Hsp10 were compared for all
three categories of patients studied. A higher percentage of individuals belonging to category 1 showed stronger reactivity to Rv2430c than to
Hsp10, but for the other two categories, the values were comparable. (B) Percentage of individuals in category 1 showing anti-IgM antibody A492
of 	0.5. A higher percentage of individuals showed anti-IgM antibody A492 of 	0.5 against Rv2430c than against Hsp10.
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of the heat shock protein family, including Hsp70 (20, 28) and
Hsp10 (28), have been known to elicit a strong B-cell response.
Surprisingly, in our study, the immunodominant antigen
Hsp10, though recognized by category 2 and 3 patient sera, was
not sensitive enough to detect the patients with fresh infections
(category 1). The picture remained unaltered when we used
PPD in place of Hsp10. It is pertinent to note that although
several antigens have been tested for use in serodiagnosis, no
test with a single antigen has proved able to achieve sensitivity
and specificity in a study population that is suitably large and
heterogeneous (3, 5, 9, 11, 13, 14, 16, 17, 18, 19, 21, 22). The
factors responsible for this include (i) the stage of the disease,
(ii) the location of the infection, and (iii) the genetic back-
ground. Our results show that the PPE protein Rv2430c, which
lacks a transmembrane domain and is therefore likely to be
cytosolic or secretory in localization, is an immunodominant
B-cell target antigen with apparent diagnostic potential. It is
also interesting to speculate on the use of Rv2430c, along with
other immunodominant antigens (10), for vaccine develop-
ment.
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